Eikon Therapeutics reported updated data on its PARP1 inhibitors non-brain-penetrant EIK1003 and CNS-penetrant EIK1004, alongside data on WRN helicase inhibitor EIK1005, all showing favorable safety profiles. The release reinforces the company's pipeline potential for 2027.